Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) at the 2025 PNS Meeting
May 09, 2025 17:00 ET | Source: Annexon Biosciences First Oral Presentation…
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
April 08, 2025 16:05 ET | Source: Annexon Biosciences Oral Presentation Features…
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR…
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
Enrollment and implant procedures completed in NIH funded feasibility study of LGS,…
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FASTs 17th Annual Global Science Summit
November 09, 2024 10:30 ET | Source: Ultragenyx Pharmaceutical Inc. Phase 1/2…